Scaling Up CareKit: Lessons Learned from Expansion of a Centralized Home HIV and Sexually Transmitted Infection Testing Program

Jenna Norelli, MPH, Maria Zlotorynska, PhD, Travis Sanchez, DVM, and Patrick S. Sullivan, DVM, PhD

Background: Despite advances in implementing human immunodeficiency virus (HIV)/sexually transmitted infection (STI) services for men who have sex with men (MSM), many remain underserved because of barriers like stigma, low facility coverage, and provider competency. This article describes the implementation of centralized nationwide mailed HIV/STI home testing (CareKit).

Methods: The Emory Center for AIDS Research developed CareKit for research study participants to request HIV self-test kits, STI specimen collection kits, and condom/lubricant packs to be shipped to any mailing address in the United States. Sexually transmitted infection kits were customized according to study needs and could include materials to collect whole blood, dried blood spots, urine sample, and rectal and pharyngeal swab samples for syphilis, gonorrhea, and chlamydia testing. Specimens were mailed back to a central Clinical Laboratory Improvement Amendments–approved laboratory for testing, and results were returned to participants.

Results: CareKit was used by 12 MSM studies and mailed 1132 STI kits to 775 participants between January 2018 and March 2020. Participants returned 507 (45%) STI kits, which included 1594 individual specimens. Eighty-one kits (16%) had at least one positive STI test result: pharyngeal chlamydia (n = 7), pharyngeal gonorrhea (n = 11), rectal chlamydia (n = 15), rectal gonorrhea (n = 12), genital chlamydia (n = 6), genital gonorrhea (n = 1), and syphilis (n = 54). In this same 2-year period, 741 HIV self-test kits were mailed to 643 MSM.

Conclusions: CareKit successfully met studies’ needs for home HIV/STI testing and diagnosed many STIs. These processes continue to be adapted for research and programs. The ability to mail home test kits has become increasingly important to reach those who may have limited access to health care services, particularly during the COVID-19 pandemic.

Men who have sex with men (MSM) in the United States are disproportionately affected by sexually transmitted bacterial infections (STIs) including syphilis, Chlamydia trachomatis (CT), and Neisseria gonorrhoeae (GC). Individuals with an STI are at increased risk for acquiring human immunodeficiency virus (HIV). Men who have sex with men have a high prevalence of extragenital CT/GC infections in the pharynx and rectum, which are often asymptomatic and underdiagnosed. Routine HIV/STI screening among sexual minorities is key to early identification, treatment, and prevention of further transmissions.

The US Centers for Disease Control and Prevention currently recommend HIV and STI screening at all exposed anatomical sites for sexually active MSM at least annually and as often as quarterly for high-risk individuals. However, barriers including sexual stigma, provider competency, and lack of access to culturally competent clinics contribute to low testing frequency in this population. Testing for HIV and STIs is lower in MSM who live in rural areas than those who live in urban areas, and improved methods are needed to increase testing among those who might reside longer distances from lesbian, gay, bisexual, transgender, queer (LGBTQ)–friendly health services.

During the past decade, self-testing and self-collection of specimens have emerged as innovative solutions to screening barriers. The Oraquick in-home HIV test (OraSure Technologies, Inc, Bethlehem, PA) received Food and Drug Administration approval for the first over-the-counter HIV test in 2012. HIV self-tests and self-collection of specimens for STI testing have been found highly acceptable among MSM, particularly oral fluid tests and collection of swab samples. Studies on the scientific integrity of home tests and self-collected samples show comparable results to traditional point-of-care tests.

The Emory University Center for AIDS Research (CFAR) Prevention Science Core developed the CareKit service to help HIV prevention-focused research studies implement home testing using a centralized mail-out system at cost. Many of these studies...
are technology-based interventions aimed at increasing access to care and prevention services among MSM.\textsuperscript{12} Thus, these interventions had a need to deliver testing services remotely through study mobile apps. CareKit has supported research studies to provide highly customized home-based testing and sexual health prevention materials to their MSM participants, growing from 2 studies in 2017 to 13 in 2020. Here, we describe the lessons learned from program implementation and expansion in the hope that future research studies can apply these methods to maximize test kit return rates and testing feasibility.

**MATERIALS AND METHODS**

The Emory CfAR Prevention Sciences Core provides HIV researchers with services to support research effort at cost. Research studies with a focus on HIV prevention and LGBTQ health can submit a request for CareKit services through the CfAR Prevention Sciences Core program manager. During the 2-year period described, one study coordinator at 50% full-time effort facilitated CareKit services with support from the CfAR Prevention Science Core manager and a part-time graduate research assistant.

OraQuick in-home HIV self-tests, STI specimen collection kits, and 9 configurations of condom/lubricant combination packs were available to participating studies. Sexually transmitted infection kits include sample collection materials with illustrated instructions, prelabeled tubes with study name and unique alphanumeric barcode ID, a prepaid overnight return mailer to ship specimens to the laboratory, a biohazard bag, return mailing instructions, and a welcome letter describing the contents of the kit and frequently asked questions. Based on study outcomes and required laboratory testing, studies can choose to collect whole blood, dried blood spot (DBS) cards, urine sample, and rectal or pharyngeal swab samples for an available panel of syphilis, HIV antibody, hepatitis, gonorrhea, or chlamydia testing. In addition, blood samples can be tested for creatinine and tenofovir diphosphate for preexposure prophylaxis (PrEP) adherence monitoring, and urine specimens could be screened for drugs of abuse. Instructional and self-collection materials were initially developed for the PrEP@Home pilot study at Emory, informed by qualitative feedback and quantitative assessment.\textsuperscript{11} Assembled STI test kits, HIV kits, and condom packs are shipped to an Amazon fulfillment center to be distributed through CareKit’s Amazon Seller Central account for multichannel fulfillment by Amazon (FBA). Sexually transmitted infection kits with collection materials, administrative costs, and shipping range from $50.26 for a DBS collection kit to $69.51 for 3-site, whole blood and DBS collection kit; laboratory fees are additional.

Participants can either order kits or be automatically sent CareKit materials according to the study requirements. Participants who can order materials through their study are shown a list of available items with pictures and descriptions in an order survey hosted by a secure, Health Insurance Portability and Accountability Act–compliant server (SurveyGizmo; Alchemer LLC, Louisville, CO). Participants consent to provide the CareKit team with a name, mailing address, and contact phone number or e-mail address with their order. Results from the order survey are uploaded by CareKit staff for processing and shipment through an Emory Amazon account. This indirect order process prevents participants from receiving targeted advertisements after placing the order through a personal Amazon account. Information from the order survey, as well as Amazon fulfillment and tracking information, are saved in a master CareKit tracking spreadsheet on Emory’s secure server, only accessible to CareKit staff.

**TABLE 1. Participating Research Studies in CareKit Program, 2018 to 2020**

| Study Name | Affiliated Institutions | Target Population | CareKit Services Used | Specimens Collected | CfAR Laboratory Test Panel |
|------------|------------------------|-------------------|-----------------------|---------------------|---------------------------|
| MMI\textsuperscript{13} | Emory and CDC | Cisgender MSM in Atlanta, NYC, and Detroit | OraQuick, STI test kits, condom packs | Urine, rectal swab, throat swab, whole blood | Syphilis RPR |
| AMIS\textsuperscript{14} | Emory | Cisgender MSM aged 15–24 y | OraQuick, STI test kits | Urine, rectal swab, whole blood, saliva, nails | Syphilis RPR, 3-site CT/GC |
| Healthmindr\textsuperscript{15} | Emory | Cisgender MSM aged 18–34 y | OraQuick, STI test kits, condom packs | Urine, rectal swab, throat swab, whole blood | Syphilis RPR, 3-site CT/GC, drug screen |
| PrEP@Home\textsuperscript{11} | Emory | Cisgender MSM aged 18–49 y | STI test kits | Urine, rectal swab, throat swab, whole blood, DBS | Syphilis RPR, 3-site CT/GC |
| LYNX\textsuperscript{16} | iTech | Cisgender MSM aged 15–24 y | OraQuick, STI test kits, condom packs | Urine, rectal swab, whole blood | Syphilis RPR, 3-site CT/GC |
| MyChoices\textsuperscript{17} | iTech | Cisgender MSM aged 15–24 y | OraQuick, STI test kits, condom packs | Urine, rectal swab, whole blood | Syphilis RPR, 3-site CT/GC |
| COMPARE\textsuperscript{12} | iTech | Cisgender MSM aged 15–24 y | OraQuick, STI test kits, condom packs | Urine, rectal swab, whole blood | Syphilis RPR, 3-site CT/GC |
| ePrEP\textsuperscript{18} | iTech | Rural, cisgender MSM aged 15–24 y | OraQuick, STI test kits, condom packs | Urine, rectal swab, whole blood | Syphilis RPR, 3-site CT/GC |
| We Prevent\textsuperscript{19} | iTech | Cisgender MSM and transgender men aged 15–24 y | STI test kits | Urine, rectal swab, whole blood | Syphilis RPR, 3-site CT/GC |
| Iowa TelePrEP\textsuperscript{20} | University of Iowa | MSM in Iowa | STI test kits | Urine, rectal swab, whole blood | Syphilis RPR, 3-site CT/GC, creatinine |
| Project Caboodle!\textsuperscript{21} | University of Michigan | MSM aged 18–34 y | STI test kit assembly (no fulfillment) | n/a | n/a |
| iSTAMP | Emory, University of Michigan, UNC | Cisgender AA and Hispanic/Latino MSM | Condom packs | n/a | n/a |
Once shipped, a CareKit team member sends a text message or e-mail with tracking information to participants. Orders arrive in a generic brown Amazon box within 3 to 10 business days after fulfillment. A follow-up text message or e-mail is sent to the participant, notifying them that their package was delivered and providing a CareKit contact number for questions, a link with video instructions, ideal days for blood specimen collection based on the laboratory processing schedule, and a link for the kit ID registration survey. The kit registration survey is used to link participants to their specimen samples via unique ID and allows specimens to be shipped to the laboratory deidentified.

OraQuick In-Home HIV tests detect antibodies in oral fluid and provide results within 20 minutes. These test kits do not require return shipment to the laboratory and are used for preliminary HIV screening. Studies with outcomes such as HIV testing frequency or compliance with screening guidelines may find OraQuicks preferable to laboratory-based HIV testing because of the ease of use and minimally invasive procedure of swabbing the upper and lower gums. Studies with HIV incidence as an outcome may prefer laboratory-based HIV testing so results can be directly accessed by the study team, and preliminary positives can be immediately retested. Studies interested in offering OraQuicks and capturing results can opt to send a survey at the time of kit delivery, requesting that participants upload a picture of the test kit.

After collecting specimens for testing, participants are asked to complete a laboratory requisition and place this form along with specimens collected in the provided packaging, which meets all federal regulations for shipment of Biological Substances, Category B. Participants ship their collected specimens via FedEx Standard Overnight to the designated laboratory in a prelabeled mailer. Urine and swab samples sent to the Clinical Laboratory Improvement Amendments–waived CfAR Clinical Virology Lab are tested using the Abbott RealTime polymerase chain reaction assay (Abbott Laboratories, Abbott Park, IL) for CT/GC. Whole blood microtainer samples from a finger prick are tested for syphilis using the ASI Rapid Plasma Reagin (RPR) Card at a 1:4 dilution. For panels with tests performed at multiple laboratories, test kits and condom packs fulfilled by CareKit were sent to addresses in 21 states with an average of 4.5 days between shipment and delivery. More than 6200 condom/lubricant packs were sent to participants across 7 studies (Fig. 1).

CareKit mailed out 1132 STI test kits to 775 study participants and 741 HIV kits to 643 study participants during this 2-year period. Of the 507 STI kits with at least one viable specimen retained for Innovative Technology (iTech). Sexually transmitted infection kits were used by 11 of the 12 studies, and HIV kits were used by 6. Five studies had collected specimens from test kits processed at multiple laboratories. Test kits and condom packs fulfilled by CareKit were sent to addresses in 21 states with an average of 4.5 days between shipment and delivery. More than 6200 condom/lubricant packs were sent to participants across 7 studies (Fig. 1).

To evaluate the success of the CareKit service, we examined the volume of HIV and STI test kits mailed, shipment timing, return of STI kits, and reporting of HIV results. For returned STI kits to the CFAR laboratory, results of the bacterial STI laboratory testing are reported by organism and anatomic site. Because some participating studies sent participants multiple test kits, we looked at return and results per kit rather than by participant.

RESULTS

Between January 2018 and March 2020, 12 research studies used CareKit services to varying degrees (Table 1). Most studies were based at Emory University with the PRISM Health team or with the Adolescent Trials Network U19 UNC/Emory Center for Innovative Technology (ITech). Sexually transmitted infection kits were used by 11 of the 12 studies, and HIV kits were used by 6. Five studies had collected specimens from test kits processed at multiple laboratories. Test kits and condom packs fulfilled by CareKit were sent to addresses in 21 states with an average of 4.5 days between shipment and delivery. More than 6200 condom/lubricant packs were sent to participants across 7 studies (Fig. 1).

CareKit mailed out 1132 STI test kits to 775 study participants and 741 HIV kits to 643 study participants during this 2-year period. Of the 507 STI kits with at least one viable specimen returned to the CFAR laboratory, 81 had one or more positive/reactive result from 1594 individual samples tested (Tables 2, 3).

| TABLE 2. CareKit Program STI Test Kit Return Rates, 2018 to 2020 |
|-----------------------------|-----------------------------|-----------------------------|
| Study                        | STI Kits Returned to CFAR Laboratory, 2018–2020 | STI Return Rate, % |
| Study                        | STI Kits Mailed          |                      |
| Studies that provided incentives for kit return |                        |                      |
| AMIS                         | 200                      | 131                   | 66 |
| cPrEP*                       | 55                       | 32                    | 58 |
| PrEP@Home*                   | 161                      | 86                    | 53 |
| (Subtotals)                  | 416                      | 249                   | 60 |
| Studies that did not provide incentives for kit return |                        |                      |
| MMI                          | 415                      | 120                   | 29 |
| LYNX                         | 40                       | 9                     | 23 |
| MyChoices                    | 25                       | 10                    | 40 |
| Iowa TelePreP                | 79                       | 72                    | 91 |
| COMPARE*                     | 11                       | 5                     | 45 |
| We Prevent*                  | 121                      | 36                    | 30 |
| Healthmindr*                 | 25                       | 6                     | 24 |
| (Subtotals)                  | 716                      | 258                   | 36 |
| Total                        | 1132                     | 507                   | 45 |

*Study is still open for enrollment, kit return rate incomplete.
TABLE 3. CareKit Program Self--Collected Specimens Tested by CfAR Laboratory Results

| Samples Returned | Samples Returned – Rejected | RPR Reactive | CT Positive | GC Positive |
|------------------|-----------------------------|--------------|-------------|-------------|
| Whole blood      | 481                         | 20           | 54 (11%)    | n/a         | n/a         |
| Urine sample     | 369                         | 0            | n/a         | 6 (2%)      | n/a         |
| Rectal swab      | 371                         | 0            | n/a         | 15 (4%)     | 12 (3%)     |
| Pharyngeal swab  | 373                         | 0            | n/a         | 7 (2%)      | 11 (3%)     |
| Total            | 1594                        | 20           | 54          | 28          | 24          |

Twenty (4%) of 481 whole blood samples returned were unable to be tested because of insufficient quantity or clotting. Kits returned from MMI, ePrEP and PrEP@Home had 3-site CT/GC and DBS testing conducted at outside laboratories and only submitted whole blood samples to CfAR.

For the AMIS study, all 200 participants received an OraQuick HIV test and were asked to report their in-home results using a secure survey e-mailed at the time of kit delivery. Participants received a $50 gift card as an incentive for returning their self-collected specimens for STI testing and for reporting their at-home HIV test result. Of the 200 participants who received an OraQuick kit, 151 (76%) participants submitted results and all but 1 uploaded a picture of the test kit for verification. Six (4%) participants reported preliminary positive results, 1 participant reported indeterminate results, and 1 participant reported not understanding their results (Table 4).

Lessons Learned

There are several key takeaways from our experience facilitating home testing across a variety of MSM studies. Comparing the 10 studies for which we processed return STI specimens, offering an incentive raised the kit return rate by 24% on average (Table 2). The 3 participating studies that incentivized kit return (AMIS, ePrEP, and PrEP@Home) had a mean (SD) return rate of 60% (5.4%). However, the study with the highest kit return rate, Iowa TelePrEP, did not provide an incentive for kit return. The studies that incentivized kit return and Iowa TelePrEP all had study outcomes related to testing or required testing in their protocols. These studies dedicated resources to kit return, whether financial or personnel time spent following up with participants. In addition, undergoing regular HIV and STI screening was required for Iowa TelePrEP, ePrEP, and PrEP@Home participants to continue accessing PrEP medication, and therefore, these participants may have been more motivated to return their specimens for testing. Studies that offered STI testing as a bonus to their intervention without an incentive averaged about a 30% return rate (MMI, Healthmindr, iSTAMP). Interruptions to both AMIS and We Prevent, and the previously described CareKit process significantly, with order data stored within the same secure, properly registered), there were 5 instances of unregistered kits with specimens returned to the laboratory that studies could not identify and results were unable to be returned.

In November 2019, CareKit established a partnership with Molecular Testing Labs (MTL; Blackfly LLC, Vancouver, WA), a Clinical Laboratory Improvement Amendments–certified laboratory with fulfillment capabilities, to take over assembly, shipment, and processing of home test kits for participating research studies as a new iteration of the program to address the concerns listed previously. This streamlined the order, shipment, and results return process significantly, with order data stored within the same secure, Health Insurance Portability and Accountability Act–compliant study portal as the laboratory results. Test kit IDs are linked to participants at shipment, which mitigates the risk of unidentifiable results. We transitioned 3 studies using CareKit to MTL in January 2020 (ePrEP, PrEP@Home, iSTAMP). Interruptions to both Amazon fulfillment services and the CfAR laboratory in March 2020 due to the COVID-19 pandemic response hastened the transition of our remaining participating studies (Healthmindr, COMPARE, and We Prevent), and the previously described CareKit process was phased out.

DISCUSSION

Studies that used the CareKit service between 2018 and 2020 had the most success when home testing was a central part of the intervention and kit return was incentivized. In addition, extragenital STI testing identified the majority of incident cases that may have otherwise gone undiagnosed. Lastly, self-reporting results from the OraQuick HIV home test kits had very high compliance (76%). Incentivized OraQuick self-reporting may be a viable alternative for study participants unable or unwilling to self-collect a blood sample for laboratory-based HIV testing, even for studies with HIV incidence as a primary or secondary outcome.

TABLE 4. AMIS Study Participants OraQuick Results Reported

| OraQuicks Ordered | Total Results Submitted | Negative Result Reported | Preliminary Positive Result Reported | Indeterminate Result Reported | Results Reported as Not Understood |
|-------------------|-------------------------|--------------------------|-------------------------------------|-------------------------------|----------------------------------|
| 200               | 151 (76%)               | 144 (95%)                | 6 (4%)                              | 1 (0.1%)                      | 1 (0.1%)                         |
among many others.26 Such as One Thousand Strong, #Testathome, and I Want the Kit, avoiding contact with busy health care facilities altogether.24,25

With the COVID-19 pandemic still out of sight, home HIV/STI testing can limit unnecessary exposure and, in conjunction with telemedicine, avoid contact with busy health care facilities altogether.24,25 Although we describe our own experiences with in-home HIV/STI testing here, other researchers and health departments have been developing and implementing home testing systems such as One Thousand Strong, #Testathome, and I Want the Kit, among many others.26–28 The value of home HIV/STI testing is becoming increasingly recognized, and we hope sharing our trial and error will help move the field in the right direction. CareKit will continue to work on expanding home HIV testing and STI self-collection in research and beyond.

**REFERENCES**

1. CDC. Sexually Transmitted Disease Surveillance 2017. Atlanta, GA: US Department of Health and Human Services, CDC, 2018. Available at: https://www.cdc.gov/std/stats17/2017-STD-Surveillance-Report_ CDC-clearance-9-10-18.pdf. Accessed January 8, 2021.
2. Johnson Jones ML, Chapin-Bardales J, Bizune D, et al. ExTRANsgential chlamydia and gonorrhea among community venue-attending men who have sex with men—five cities, United States, 2017. MMWR Morb Mortal Wkly Rep 2019; 68:321–325.
3. Dewart CM, Bernstein KT, DeGroote NP, et al. Prevalence of rectal chlamydial and gonococcal infections: A systematic review. Sex Transm Dis 2018; 45:287–293.
4. Workowski KA, Bolan GA, Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines, 2015 [published correction appears in MMWR Recomm Rep 2015 Aug 28;64(3):924].
5. MMWR Recomm Rep 2015; 64(RR-03):1–137.
6. Lutz AR. Screening for asymptomatic extragenital gonorrhea and chlamydia in men who have sex with men: significance, recommendations, and options for overcoming barriers to testing. LGBT Health January 2015; 2:27–34.
7. Sanchez TH, Zlotorzynska M, Sineath RC, et al. National trends in sexual behavior, substance use and HIV testing among United States men who have sex with men recruited online, 2013 through 2017. AIDS Behav 2018; 22:4243–4245.
8. McKenney J, Sullivan PS, Bowles K, et al. HIV risk behaviors and utility of prevention services, urban and rural men who have sex with men in the United States: Results from a national online survey. AIDS Behav 2018; 22:2127–2136.
9. Siegler AJ, Bratcher A, Weiss KM. Geographic access to preexposure prophylaxis clinics among men who have sex with men in the United States. Am J Public Health 2019; 109:1216–1223.
10. Food and Drug Administration. Approval Letter, OraQuick In-Home HIV Test. Published July 3, 2012. Available at: https://www.fda.gov/vaccines-blood-biologics/approved-biologics-drugs/oraquick-in-home-hiv-test.
11. Figueoar C, Johnson C, Verster A, et al. Attitudes and acceptability on HIV self-testing among key populations: A literature review. AIDS Behav 2015; 19:1949–1965.
12. Siegler AJ, Mayer KH, Liu AY, et al. Developing and assessing the feasibility of a home-based preexposure prophylaxis monitoring and support program. Clin Infect Dis 2019; 68:501–504.
13. Hightow-Weidman LB, Muesig K, Rosenberg E, et al. University of North Carolina/Emory Center for Innovative Technology (iTech) for addressing the HIV epidemic among adolescents and young adults in the United States: Protocol and rationale for center development. JMIR Res Protoc 2018; 7:e10365.
14. Sullivan PS, Zahn RJ, Wiatrix S, et al. HIV prevention via mobile messaging for men who have sex with men (M-Cubed): Protocol for a randomized controlled trial. JMIR Res Protoc 2019; 8:e16439.
15. Sanchez TH, Sineath RC, Kahle EM, et al. The Annual American Men’s Internet Survey of Behaviors of Men Who Have Sex with Men in the United States: Protocol and key indicators report 2013. JMIR Public Health Surveill 2015; 1:e3.
16. Jones J, Dominguez K, Stephenson R, et al. A theoretically based mobile app to increase pre-exposure prophylaxis uptake among men who have sex with men: Protocol for a randomized controlled trial. JMIR Res Protoc 2020; 9:e16231.
17. Liu A, Coleman K, Bogar JC, et al. Developing a mobile app (LYNX) to support linkage to HIV sexually transmitted infection testing and pre-exposure prophylaxis for young men who have sex with men: Protocol for a randomized controlled trial. JMIR Res Protoc 2019; 8:e10659.
18. Siegler AJ, Brock JB, Hurt CB, et al. An electronic pre-exposure prophylaxis initiation and maintenance home care system for nonurban young men who have sex with men: Protocol for a randomized controlled trial. JMIR Res Protoc 2019; 8:e13982.
19. Gavare KE, Darbess LA, Hightow-Weidman L, et al. The development and testing of a relationship skills intervention to improve HIV prevention uptake among young gay, bisexual, and other men who have sex with men and their primary partners (We Prevent): Protocol for a randomized controlled trial. JMIR Res Protoc 2019; 8:e10370.
20. Hoth AB, Shafer C, Dillon DB, et al. Iowa TelePEP: A public-health-partnered telehealth model for human immunodeficiency virus preexposure prophylaxis delivery in a rural state. Sex Transm Dis 2019; 46:507–512.
21. Sharma A, Stephenson R, Sallabank G, et al. Acceptability and feasibility of self-collecting biological specimens for HIV, sexually transmitted infection, and adherence testing among high-risk populations (Project Caboodle!): Protocol for an exploratory mixed-methods study. JMIR Res Protoc 2019; 8:e13647.
22. TakeMeHome. Building Healthy Communities Online. Available at: https://takemehome.org/. Published 2021. Accessed February 25, 2021.
23. TakeMeHome Together. Insignia Federal Group Inc. Available at: https://together.takemehome.org/. Published 2021. Accessed February 3, 2021.
24. Sanchez TH, Zlotorzynska M, Rai M, et al. Characterizing the impact of COVID-19 on men who have sex with men across the United States in April, 2020. AIDS Behav 2020; 24:2024–2032.
25. Hightow-Weidman L, Muesig K, Claude K, et al. Maximizing digital interventions for youth in the midst of COVID-19: Lessons from the Adolescent Trials Network for HIV Interventions. AIDS Behav 2020; 24:2239–2243.
26. Cuvic D, Whitfield TH, et al. Recruiting a U.S. national sample of HIV-negative gay and bisexual men to complete at-home self-administered HIV/STI testing and surveys: Challenges and opportunities. Sex Res Social Policy 2016; 13:1–21.
27. Hubbard SJ, Ma M, Wahnich A, et al. #Testathome: Implementing 2 phases of a HIV self-testing program through community-based organization partnerships in New York City. Sex Transm Dis 2020; 47:ss Suppl 1): S49–S52.
28. Heggernes E, Jett-Goeheen M, Gaydos CA. An analysis of user survey data for an Internet program for testing for sexually transmitted infections. I Want the Kit, in Maryland and Washington, DC. Sex Transm Dis 2019; 46:768–770.